More recently, a highly specific MCL1 inhibitor, S63845, was shown to have potent anti-tumour activity as a single-agent in preclinical leukaemia models [29], as well as in combination with ABT-199 in BC PDX studies [30]. Here, MCL1 is linked to neoplasm.